Literature DB >> 35095131

Update on Optic Neuritis: An International View.

Simon J Hickman1, Axel Petzold2,3,4,5.   

Abstract

Previously, optic neuritis was thought to be typical, i.e. idiopathic or multiple sclerosis (MS) related, associated with a good visual prognosis, or atypical, i.e. not associated with MS and requiring corticosteroids or plasma exchange for vision to recover. More recently, the importance of optic neuritis in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein (MOG) antibody disease has become more appreciated. The results of the Optic Neuritis Treatment Trial (ONTT) has influenced how optic neuritis is treated around the world. For this review we surveyed the international literature on optic neuritis in adults. Our aims were first to find the reported incidence of optic neuritis in different countries and to ascertain what percentage of cases were seropositive for anti-aquaporin 4 and anti-MOG antibodies, and second, to document the presenting features, treatment, and outcomes from a first episode of the different types of optic neuritis from these countries, and to compare the results with the outcomes of the ONTT cohort. From these data we have sought to highlight where ambiguities currently lie in how to manage optic neuritis and have made recommendations as to how future treatment trials in optic neuritis should be carried out in the current antibody testing era.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Optic neuritis; corticosteroids; epidemiology; global health; myelin oligodendrocyte antibody disease; neuromyelitis optica spectrum disorder

Year:  2021        PMID: 35095131      PMCID: PMC8794242          DOI: 10.1080/01658107.2021.1964541

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  89 in total

1.  Epidemiologic and clinical features of optic neuritis in the 20th and 21st sanitary districts of the Sardinia (Italy).

Authors:  S Congia; M A Vacca; S Tronci
Journal:  Acta Neurol (Napoli)       Date:  1989-02

2.  Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study.

Authors:  Osamu Mimura; Hitoshi Ishikawa; Takeshi Kezuka; Keigo Shikishima; Tone Suzuki; Makoto Nakamura; Hideki Chuman; Kenji Inoue; Akiko Kimura; Akiko Yamagami; Maki Mihoya; Yuzo Nakao
Journal:  Jpn J Ophthalmol       Date:  2021-01-20       Impact factor: 2.447

Review 3.  The investigation of acute optic neuritis: a review and proposed protocol.

Authors:  Axel Petzold; Mike P Wattjes; Fiona Costello; Jose Flores-Rivera; Clare L Fraser; Kazuo Fujihara; Jacqueline Leavitt; Romain Marignier; Friedemann Paul; Sven Schippling; Christian Sindic; Pablo Villoslada; Brian Weinshenker; Gordon T Plant
Journal:  Nat Rev Neurol       Date:  2014-07-08       Impact factor: 42.937

4.  [Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)].

Authors:  M Wakakura; S Ishikawa; S Oono; A Tabuchi; K Kani; Y Tazawa; Y Nakao; M Kiyosawa; K Kawai; A Oohira
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1995-01

Review 5.  Neurological update: MOG antibody disease.

Authors:  Ray Wynford-Thomas; Anu Jacob; Valentina Tomassini
Journal:  J Neurol       Date:  2018-12-19       Impact factor: 4.849

6.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.

Authors:  Boyan Fang; Andrew McKeon; Shannon R Hinson; Thomas J Kryzer; Sean J Pittock; Allen J Aksamit; Vanda A Lennon
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

7.  Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.

Authors:  Eugenia Martinez-Hernandez; Maria Sepulveda; Kevin Rostásy; Romana Höftberger; Francesc Graus; Robert J Harvey; Albert Saiz; Josep Dalmau
Journal:  JAMA Neurol       Date:  2015-02       Impact factor: 18.302

8.  Understanding and misunderstanding randomized controlled trials.

Authors:  Angus Deaton; Nancy Cartwright
Journal:  Soc Sci Med       Date:  2017-12-25       Impact factor: 5.379

9.  Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies.

Authors:  Haeng-Jin Lee; Boram Kim; Patrick Waters; Mark Woodhall; Sarosh Irani; Sohyun Ahn; Seong-Joon Kim; Sung-Min Kim
Journal:  J Neuroinflammation       Date:  2018-10-31       Impact factor: 8.322

10.  Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis.

Authors:  Linda Hansapinyo; Chayanee Vivattanaseth
Journal:  Open Ophthalmol J       Date:  2018-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.